CN118955402A - Kv7通道激活剂组合物和使用方法 - Google Patents
Kv7通道激活剂组合物和使用方法 Download PDFInfo
- Publication number
- CN118955402A CN118955402A CN202410835028.0A CN202410835028A CN118955402A CN 118955402 A CN118955402 A CN 118955402A CN 202410835028 A CN202410835028 A CN 202410835028A CN 118955402 A CN118955402 A CN 118955402A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- optionally substituted
- cor
- och
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
- C07D235/32—Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862644932P | 2018-03-19 | 2018-03-19 | |
| US201862644902P | 2018-03-19 | 2018-03-19 | |
| US62/644,932 | 2018-03-19 | ||
| US62/644,902 | 2018-03-19 | ||
| US201862663438P | 2018-04-27 | 2018-04-27 | |
| US62/663,438 | 2018-04-27 | ||
| US201862697198P | 2018-07-12 | 2018-07-12 | |
| US62/697,198 | 2018-07-12 | ||
| CN201980033266.7A CN112771039A (zh) | 2018-03-19 | 2019-03-19 | Kv7通道激活剂组合物和使用方法 |
| PCT/US2019/023039 WO2019183148A1 (en) | 2018-03-19 | 2019-03-19 | Kv7 channel activators compositions and methods of use |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980033266.7A Division CN112771039A (zh) | 2018-03-19 | 2019-03-19 | Kv7通道激活剂组合物和使用方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118955402A true CN118955402A (zh) | 2024-11-15 |
Family
ID=67905138
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410835028.0A Pending CN118955402A (zh) | 2018-03-19 | 2019-03-19 | Kv7通道激活剂组合物和使用方法 |
| CN202410805545.3A Pending CN118955400A (zh) | 2018-03-19 | 2019-03-19 | Kv7通道激活剂组合物和使用方法 |
| CN202410805542.XA Pending CN119118926A (zh) | 2018-03-19 | 2019-03-19 | Kv7通道激活剂组合物和使用方法 |
| CN201980033266.7A Pending CN112771039A (zh) | 2018-03-19 | 2019-03-19 | Kv7通道激活剂组合物和使用方法 |
| CN202410840828.1A Pending CN118955403A (zh) | 2018-03-19 | 2019-03-19 | Kv7通道激活剂组合物和使用方法 |
| CN202410827103.9A Pending CN118955401A (zh) | 2018-03-19 | 2019-03-19 | Kv7通道激活剂组合物和使用方法 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410805545.3A Pending CN118955400A (zh) | 2018-03-19 | 2019-03-19 | Kv7通道激活剂组合物和使用方法 |
| CN202410805542.XA Pending CN119118926A (zh) | 2018-03-19 | 2019-03-19 | Kv7通道激活剂组合物和使用方法 |
| CN201980033266.7A Pending CN112771039A (zh) | 2018-03-19 | 2019-03-19 | Kv7通道激活剂组合物和使用方法 |
| CN202410840828.1A Pending CN118955403A (zh) | 2018-03-19 | 2019-03-19 | Kv7通道激活剂组合物和使用方法 |
| CN202410827103.9A Pending CN118955401A (zh) | 2018-03-19 | 2019-03-19 | Kv7通道激活剂组合物和使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US10851067B2 (https=) |
| EP (1) | EP3768677A4 (https=) |
| JP (2) | JP7757036B2 (https=) |
| KR (3) | KR102731128B1 (https=) |
| CN (6) | CN118955402A (https=) |
| AU (3) | AU2019239955B2 (https=) |
| BR (1) | BR112020018933A2 (https=) |
| CA (1) | CA3093976A1 (https=) |
| IL (2) | IL277419B2 (https=) |
| MX (2) | MX2020009693A (https=) |
| SG (1) | SG11202008030WA (https=) |
| WO (1) | WO2019183148A1 (https=) |
| ZA (1) | ZA202308070B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3572405T1 (sl) * | 2014-09-12 | 2023-12-29 | Biohaven Therapeutics Ltd. | Amidi benzoimidazol-1,2-il kot aktivatorji kanalov kv 7 |
| CN118955402A (zh) * | 2018-03-19 | 2024-11-15 | 诺普生物科学有限责任公司 | Kv7通道激活剂组合物和使用方法 |
| BR112022004847A2 (pt) * | 2019-09-17 | 2022-06-07 | Knopp Biosciences Llc | Método para tratar uma doença ou distúrbio de neurodesenvolvimento |
| CA3266454A1 (en) * | 2022-08-30 | 2024-03-07 | Biohaven Therapeutics Ltd. | POLYTHERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS |
| AU2023338196A1 (en) * | 2022-09-06 | 2025-04-10 | Biohaven Therapeutics Ltd. | Combination therapies including metal channel activators |
| KR20260049605A (ko) * | 2023-08-10 | 2026-04-14 | 바이오하벤 테라퓨틱스 리미티드 | Kv7.2/7.3 칼륨 채널 활성제의 서방형 제형 |
| IL326832A (en) * | 2023-09-15 | 2026-04-01 | Biohaven Therapeutics Ltd | Methods for treating epilepsy and related disorders using potent and selective potassium channel activators |
| WO2025103406A1 (zh) * | 2023-11-15 | 2025-05-22 | 南京明德新药研发有限公司 | 6并5杂芳基衍生物及其应用 |
| WO2025137661A1 (en) * | 2023-12-22 | 2025-06-26 | Biohaven Therapeutics Ltd. | Combination treatment of neurological disorders |
| US20260049061A1 (en) * | 2024-03-18 | 2026-02-19 | HUMANWELL PHARMACEUTICAL US, Inc. | Small molecules as kcnq2/3 (kv7.2/3) channel activators and their medical use thereof |
| WO2026042005A1 (en) | 2024-08-18 | 2026-02-26 | Biohaven Therapeutics Ltd. | Prodrugs of benzimidazol-1,2-yl amide compounds |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0772181B2 (ja) | 1989-06-26 | 1995-08-02 | 株式会社大塚製薬工場 | ベンズイミダゾール誘導体 |
| JPH0772181A (ja) | 1993-09-03 | 1995-03-17 | Advantest Corp | 電位波形測定方法および装置 |
| GB9413724D0 (en) | 1994-07-07 | 1994-08-24 | Wellcome Found | Therapeutic nucleosides |
| US6855714B2 (en) | 2001-07-06 | 2005-02-15 | Schering Aktiengesellschaft | 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives |
| SE0301701D0 (sv) | 2003-06-10 | 2003-06-10 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| WO2007017764A2 (en) * | 2005-05-18 | 2007-02-15 | Neuraxon, Inc. | Substituted benzimidazole compounds with dual nos inhibitory activity and muopioid agonist activity |
| CN101516873A (zh) * | 2006-10-03 | 2009-08-26 | 神经研究公司 | 用作钾通道调节剂的吲唑基衍生物 |
| EP2186804B1 (en) | 2007-08-10 | 2015-06-17 | Nippon Soda Co., Ltd. | Nitrogen-containing heterocyclic compound and pest control agent |
| TWI482768B (zh) | 2007-11-22 | 2015-05-01 | Zenyaku Kogyo Kk | 雜環化合物之非晶質體、含有其之固體分散體、藥劑及其製法 |
| GB0723794D0 (en) | 2007-12-05 | 2008-01-16 | Lectus Therapeutics Ltd | Potassium ion channel modulators and uses thereof |
| AU2008343813B2 (en) | 2007-12-19 | 2012-04-12 | Amgen Inc. | Inhibitors of PI3 kinase |
| WO2010051819A1 (en) | 2008-11-10 | 2010-05-14 | Neurosearch A/S | Novel 2,3-diamino-quinazolinone derivatives and their medical use |
| US8232273B2 (en) | 2008-12-19 | 2012-07-31 | Genentech, Inc. | Heterocyclic compounds and methods of use |
| CA2804165C (en) | 2010-07-08 | 2015-02-24 | Pfizer Inc. | Piperidinyl pyrimidine amides as kv7 potassium channel openers |
| CN103168032A (zh) | 2010-08-05 | 2013-06-19 | 安美基公司 | 抑制间变性淋巴瘤激酶的苯并咪唑和氮杂苯并咪唑化合物 |
| US9650376B2 (en) | 2013-03-15 | 2017-05-16 | Knopp Biosciences Llc | Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators |
| WO2015023958A1 (en) * | 2013-08-15 | 2015-02-19 | The University Of Kansas | Toll-like receptor agonists |
| SI3572405T1 (sl) | 2014-09-12 | 2023-12-29 | Biohaven Therapeutics Ltd. | Amidi benzoimidazol-1,2-il kot aktivatorji kanalov kv 7 |
| CN118955402A (zh) * | 2018-03-19 | 2024-11-15 | 诺普生物科学有限责任公司 | Kv7通道激活剂组合物和使用方法 |
| BR112022004847A2 (pt) * | 2019-09-17 | 2022-06-07 | Knopp Biosciences Llc | Método para tratar uma doença ou distúrbio de neurodesenvolvimento |
-
2019
- 2019-03-19 CN CN202410835028.0A patent/CN118955402A/zh active Pending
- 2019-03-19 AU AU2019239955A patent/AU2019239955B2/en active Active
- 2019-03-19 IL IL277419A patent/IL277419B2/en unknown
- 2019-03-19 BR BR112020018933-2A patent/BR112020018933A2/pt unknown
- 2019-03-19 CA CA3093976A patent/CA3093976A1/en active Pending
- 2019-03-19 US US16/358,642 patent/US10851067B2/en active Active
- 2019-03-19 KR KR1020207029659A patent/KR102731128B1/ko active Active
- 2019-03-19 KR KR1020247037753A patent/KR102868652B1/ko active Active
- 2019-03-19 CN CN202410805545.3A patent/CN118955400A/zh active Pending
- 2019-03-19 CN CN202410805542.XA patent/CN119118926A/zh active Pending
- 2019-03-19 CN CN201980033266.7A patent/CN112771039A/zh active Pending
- 2019-03-19 JP JP2020551340A patent/JP7757036B2/ja active Active
- 2019-03-19 CN CN202410840828.1A patent/CN118955403A/zh active Pending
- 2019-03-19 WO PCT/US2019/023039 patent/WO2019183148A1/en not_active Ceased
- 2019-03-19 KR KR1020257032902A patent/KR20250150168A/ko active Pending
- 2019-03-19 SG SG11202008030WA patent/SG11202008030WA/en unknown
- 2019-03-19 EP EP19772264.8A patent/EP3768677A4/en active Pending
- 2019-03-19 MX MX2020009693A patent/MX2020009693A/es unknown
- 2019-03-19 CN CN202410827103.9A patent/CN118955401A/zh active Pending
- 2019-03-19 IL IL310136A patent/IL310136A/en unknown
-
2020
- 2020-09-17 MX MX2023001153A patent/MX2023001153A/es unknown
- 2020-10-22 US US17/077,068 patent/US11261162B2/en active Active
-
2022
- 2022-01-07 US US17/570,536 patent/US11724990B2/en active Active
-
2023
- 2023-06-20 US US18/338,096 patent/US12286408B2/en active Active
- 2023-08-21 ZA ZA2023/08070A patent/ZA202308070B/en unknown
- 2023-11-16 JP JP2023195267A patent/JP2024026104A/ja active Pending
- 2023-11-17 AU AU2023266373A patent/AU2023266373B2/en active Active
-
2024
- 2024-04-17 AU AU2024202496A patent/AU2024202496A1/en active Pending
-
2025
- 2025-03-29 US US19/094,862 patent/US20260062389A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN118955402A (zh) | Kv7通道激活剂组合物和使用方法 | |
| CN104725359B (zh) | 取代的哌嗪化合物及其使用方法和用途 | |
| AU2003223093A1 (en) | Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor | |
| TW201904942A (zh) | 經取代５-氰基吲哚化合物及其用途 | |
| TW202332439A (zh) | ｐ３８ ＭＡＰＫ／ＭＫ２通路調節劑及其組合物、製備方法和用途 | |
| US10420772B2 (en) | Animal and human anti-trypanosomonal and anti-leishmania agents | |
| HK40120047A (zh) | Kv7通道激活剂组合物和使用方法 | |
| HK40119318A (zh) | Kv7通道激活剂组合物和使用方法 | |
| HK40118422A (zh) | Kv7通道激活剂组合物和使用方法 | |
| HK40119317A (zh) | Kv7通道激活剂组合物和使用方法 | |
| HK40119631A (zh) | Kv7通道激活剂组合物和使用方法 | |
| CN120569387A (zh) | Par2的小分子调节剂及其用途 | |
| WO2026059838A1 (en) | Indazole derivatives useful as hcn1/hcn 2 modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40119631 Country of ref document: HK |